Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Invested Capital (2020 - 2025)

Gain Therapeutics has reported Invested Capital over the past 6 years, most recently at $6.0 million for Q3 2025.

  • Quarterly results put Invested Capital at $6.0 million for Q3 2025, down 33.15% from a year ago — trailing twelve months through Sep 2025 was $6.0 million (down 33.15% YoY), and the annual figure for FY2024 was $7.4 million, down 41.33%.
  • Invested Capital for Q3 2025 was $6.0 million at Gain Therapeutics, up from $3.8 million in the prior quarter.
  • Over the last five years, Invested Capital for GANX hit a ceiling of $44.5 million in Q1 2021 and a floor of $3.8 million in Q2 2025.
  • Median Invested Capital over the past 5 years was $12.7 million (2023), compared with a mean of $18.9 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 63122.01% in 2021 and later crashed 67.87% in 2025.
  • Gain Therapeutics' Invested Capital stood at $34.9 million in 2021, then tumbled by 45.63% to $19.0 million in 2022, then crashed by 33.13% to $12.7 million in 2023, then plummeted by 41.33% to $7.4 million in 2024, then decreased by 18.99% to $6.0 million in 2025.
  • The last three reported values for Invested Capital were $6.0 million (Q3 2025), $3.8 million (Q2 2025), and $5.9 million (Q1 2025) per Business Quant data.